Therapy News and Research

RSS

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

A new subcutaneous formulation of RoActemra® (tocilizumab) has today been launched providing thousands of UK rheumatoid arthritis (RA) patients with a potentially life-changing treatment option.1

19 May 2014

Implantable system improves sleep and heart function without mask

A novel device implanted under the skin like a pacemaker successfully treats central sleep apnoea (CSA) in heart failure patients, according to research presented today at the Heart Failure Congress 2014, held 17-20 May in Athens, Greece.

19 May 2014

ICD, CRT-D patients benefit to almost equivalent extent from home telemonitoring

Home telemonitoring is equally effective in ICD and CRT-D patients, a subanalysis of the IN-TIME trial has shown.

19 May 2014

Umbian announces outcome of new study for U-Sleep automated messaging system

Umbian Inc., a ResMed (NYSE: RMD) company, and leading provider of cloud-based healthcare compliance solutions, today announced the outcome of a new study that shows significant, measurable efficiency gains when using the automated messaging capabilities of its U-Sleep compliance management solution.

19 May 2014

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

The PARADIGM-HF trial has been stopped early for a benefit to patients that was overwhelmingly statistically significant.

19 May 2014

Patients with chronic pulmonary thromboembolic disease may benefit from PTE

Patients with chronic pulmonary thromboembolic disease may benefit from pulmonary thromboendarterectomy (PTE), even if the patients don't have severe pulmonary hypertension, according to University of California, San Diego, researchers.

19 May 2014

Study examines predictors and effects of testosterone therapy

Three new studies examining the predictors, effects and durability of testosterone therapy on men will be presented to reporters at the 109th Annual Scientific Meeting of the American Urological Association (AUA) during a special press conference in the Orange County Convention Center, Orlando, FL on Sunday, May 18 at 2:00 p.m. ET.

19 May 2014

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.

19 May 2014

TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that results from a real-life, retrospective, observational study of QVAR- will be presented at the American Thoracic Society (ATS) 2014 International Conference in San Diego on May 18, 2014.

19 May 2014

Low risk prostate cancer not always low risk

More and more men who believe they have low-risk prostate cancers are opting for active surveillance, forgoing treatment and monitoring the cancer closely with prostate-specific antigen (PSA) tests, digital rectal exams and ultrasounds at regular intervals to see if their tumors are growing. Nearly 400 men are now enrolled in the UCLA Active Surveillance program, the largest in Southern California.

19 May 2014

Study shows commonly used statin drug does not reduce acute COPD exacerbations

A statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD), according to the results of a large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA.

19 May 2014

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the first quarter ended March 31, 2014.

17 May 2014

$Fracture liaison service reduces risk of fragility fractures in older adults$

Fracture liaison service reduces risk of fragility fractures in older adults

Studies have shown that anyone age 50 or older who suffers a fragility fracture – a bone break sustained in a fall from a standing height or less – is two to five times more likely to experience a second fracture than someone who hasn't had one. The odds that a person who's suffered two such fractures will have a third are even higher.

17 May 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of the Company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema).

16 May 2014

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer.

16 May 2014

MD Anderson Cancer Center, Concord Medical sign consulting agreement for cancer hospital projects

Concord Medical Services Holdings Limited ("Concord Medical" or the "Company"), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced it has engaged The University of Texas MD Anderson Cancer Center ("MD Anderson") as a consultant for its cancer hospital projects under planning in Shanghai and Beijing.

16 May 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

State highlights: 700 nurses needed for health care help in Calif. county; Missouri abortion wait period; nursing home funding in Maine

A selection of health policy stories from California, Missouri, Maine, Michigan, North Carolina, Texas and Georgia.

16 May 2014

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has successfully completed a Phase II trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder.

16 May 2014

Therapy News and Research

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

Implantable system improves sleep and heart function without mask

ICD, CRT-D patients benefit to almost equivalent extent from home telemonitoring

Umbian announces outcome of new study for U-Sleep automated messaging system

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

Patients with chronic pulmonary thromboembolic disease may benefit from PTE

Study examines predictors and effects of testosterone therapy

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

Low risk prostate cancer not always low risk

Study shows commonly used statin drug does not reduce acute COPD exacerbations

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Fracture liaison service reduces risk of fragility fractures in older adults

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

MD Anderson Cancer Center, Concord Medical sign consulting agreement for cancer hospital projects

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

State highlights: 700 nurses needed for health care help in Calif. county; Missouri abortion wait period; nursing home funding in Maine

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News